Management of Hyperphosphataemia in Chronic Kidney Disease: Summary of National Institute for Health and Clinical Excellence (NICE) Guideline

I. Dasgupta, R. Shroff, D. Bennett-Jones, G. McVeigh

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)

Abstract

Bone disease and ectopic calcification are the two main consequences of hyperphosphataemia of chronic kidney disease (CKD). Observational studies have demonstrated that hyperphosphataemia in CKD is associated with increased mortality. Furthermore, the use of phosphate binders in dialysis patients is associated with significantly lower mortality. The UK Renal Registry data show significant underachievement of phosphate targets in dialysis patients. It is believed to be due to wide variation in how management interventions are used. The National Institute for Health and Clinical Excellence (NICE) has developed a guideline on the management of hyperphosphataemia in CKD. This is based on the evidence currently available using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. This review outlines the recommendations including research recommendations and discusses methodology, rationale and challenges faced in developing this guideline and the health economic model used to assess the cost-effectiveness of different phosphate binders. © 2013 S. Karger AG, Basel.
Original languageEnglish
Pages (from-to)1-9
JournalNephron. Clinical practice
Volume124
Issue number1-2
DOIs
Publication statusPublished - Dec 2013

Fingerprint Dive into the research topics of 'Management of Hyperphosphataemia in Chronic Kidney Disease: Summary of National Institute for Health and Clinical Excellence (NICE) Guideline'. Together they form a unique fingerprint.

Cite this